It would have been very interesting to evaluate differences in prevalence of JAK2 mutation and clinical consequences between these two groups, considering the relative high incidence of myeloproliferative neoplasm in the MVT group [5]. This evidence concerns the gene JAK2 and myeloproliferative disorder.